Pfizer ( PFE) says it will delay the launch of its inhaled insulin Exubera until September, several weeks later than originally planned. Previously, Pfizer said the drug would be available in mid-July . Although Exubera was approved by the Food and Drug Administration in January and made available in Germany and Ireland in May, Pfizer executives said Thursday that they wanted to make sure U.S. educational programs for doctors, pharmacists, diabetes educators and patients cover all the bases. "We will never get a second chance" to introduce the first inhaled insulin, said Hank McKinnell, Pfizer's chairman and CEO, in a telephone conference call with analysts. "Our education programs and manufacturing preparations are time-consuming, but we are taking the time necessary to do the job right," said Karen Katen, a vice chairman who is in charge of Pfizer's human-health products. "We are working to meet not only initial demand for the medicine, but also continued demand from prescription refills. Initial supplies of Exubera will be available across the U.S. beginning in September." Pfizer will be providing "starter kits" to selected physicians next week. The kits will contain the dry-powder insulin that's administered through an inhaler. The samples will be sent to doctors who are heavy prescribers of insulin to control diabetics' blood sugar levels. Exubera is prescribed for both type 1 and type 2 diabetics. Most diabetics belong to the latter category, meaning their bodies can't produce enough insulin or can't properly process insulin. Type 1 diabetics can't produce insulin, the hormone that converts sugar into fuel for the body's cells. Company officials told analysts they don't have enough information on sales in Germany or Ireland to assess Exubera's progress, and they said they wouldn't be able to gauge its U.S. performance until late 2006 or early 2007. The company didn't comment on Exubera's pricing, although at least one analyst has said it will be 33% to 40% higher than injectable insulin .